Dilafor Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Dilafor General Information

Description

Producer of pharmaceutical products intended to contribute towards healthy lives for mothers, children, and families. The company's products are proprietary heparan sulfate mimetics for the optimal effectiveness of oxytocin and prostaglandins which severe fetal asphyxia and postpartum hemorrhage, enabling physicians to reduce these risks associated with protracted labor.

Contact Information

Website
www.dilafor.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Karolinska Institutet Science Park
  • Fogdevreten 2A
  • 171 65 Solna
  • Sweden
+46 070-790
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • Karolinska Institutet Science Park
  • Fogdevreten 2A
  • 171 65 Solna
  • Sweden
+46 070-790

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dilafor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private Completed Generating Revenue
10. Later Stage VC 31-Dec-2021 Completed Generating Revenue
9. Later Stage VC 23-Apr-2019 Completed Generating Revenue
8. Later Stage VC 31-Dec-2018 Completed Generating Revenue
7. Later Stage VC 31-Dec-2017 Completed Generating Revenue
6. Later Stage VC 27-Sep-2016 Completed Generating Revenue
5. Later Stage VC 31-Dec-2014 Completed Generating Revenue
4. Later Stage VC 31-Dec-2013 Completed Generating Revenue
3. Secondary Transaction - Private 13-Feb-2013 $3.01M Completed Generating Revenue
2. Later Stage VC 31-Dec-2011 $3.01M $3.01M Completed Generating Revenue
To view Dilafor’s complete valuation and funding history, request access »

Dilafor Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference
Preference
Preference
Preference
Preference
Preference
Preference
Preference 20,974 $54.87 $54.87 1x $54.87 1.58%
Preference 36,599 $61.77 $61.77 1x $61.77 2.75%
To view Dilafor’s complete cap table history, request access »

Dilafor Patents

  • 73

    Total Documents Applications and Grants

  • Total Patents Families

  • 35

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

Dilafor Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230355658-A1 Medical use of tafoxiparin Pending 03-May-2022
EP-4272749-A1 New medical use of tafoxiparin Pending 03-May-2022
AU-2021223494-A1 Tafoxiparin for the treatment of preeclampsia Pending 17-Feb-2020
EP-4106765-A1 Tafoxiparin for the treatment of preeclampsia Pending 17-Feb-2020
JP-2023512920-A Tafoxipalin for the treatment of preeclampsia Pending 17-Feb-2020 A61K31/727
To view Dilafor’s complete patent history, request access »

Dilafor Executive Team (17)

Name Title Board Seat
Lena Wikingsson Ph.D Chief Executive Officer
Karin Soderberg Clinical Research Director
Gunvor Ordeberg Ph.D CMO
Erik Holmer Ph.D Co-Founder, Head & Director of Research & Development & Board Member
Per Eriksson Co-Founder & Head of Manufacturing
You’re viewing 5 of 17 executive team members. Get the full list »

Dilafor Board Members (13)

Name Representing Role Since
Enrica Bovina Self Board Member
Fredrik Ahlström Self Board Member
Johan Rasin Dilafor Co-Founder & Board Member
Marco Vecchia Self Board Member
Raffaele Caldarone Advant Nctm Board Member
You’re viewing 5 of 13 board members. Get the full list »

Dilafor Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dilafor Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Opocrin Corporation Minority
Lee's Pharmaceutical Holdings Corporation Minority
Östersjöstiftelsen Limited Partner Minority
Pila Pharma Corporation Minority
b2venture Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Dilafor FAQs

  • When was Dilafor founded?

    Dilafor was founded in 2003.

  • Who is the founder of Dilafor?

    Erik Holmer Ph.D, Per Eriksson, Kjell Gunnarsson, Göran Kvist, Johan Rasin, Tore Mellstrand Ph.D, Anders Malmström Ph.D, Hans-Peter Ekre, Mats Wahlgren Ph.D, Per Giléus, and Ulf Lindahl Ph.D are the founders of Dilafor.

  • Who is the CEO of Dilafor?

    Lena Wikingsson Ph.D is the CEO of Dilafor.

  • Where is Dilafor headquartered?

    Dilafor is headquartered in Solna, Sweden.

  • What is the size of Dilafor?

    Dilafor has 4 total employees.

  • What industry is Dilafor in?

    Dilafor’s primary industry is Drug Discovery.

  • Is Dilafor a private or public company?

    Dilafor is a Private company.

  • What is Dilafor’s current revenue?

    The current revenue for Dilafor is .

  • How much funding has Dilafor raised over time?

    Dilafor has raised $26.5M.

  • Who are Dilafor’s investors?

    Opocrin, Lee's Pharmaceutical Holdings, Östersjöstiftelsen, Pila Pharma, and b2venture are 5 of 7 investors who have invested in Dilafor.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »